Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.000128 | uM | 12305.155 | 0.9906 | 0.9934 | 2.8841 | |
| BT-549 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.00064 | uM | 12305.155 | 0.9539 | 0.9676 | 2.8841 | |
| BT-549 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.0032 | uM | 12305.155 | 0.9535 | 0.9672 | 2.8841 | |
| BT-549 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.016 | uM | 12305.155 | 0.9081 | 0.9343 | 2.8841 | |
| BT-549 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.08 | uM | 12305.155 | 0.9104 | 0.9360 | 2.8841 | |
| BT-549 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.4 | uM | 12305.155 | 0.7745 | 0.8304 | 2.8841 | |
| BT-549 | TNBC | Basal B | Selumetinib | MEK | MAPK | 2 | uM | 12305.155 | 0.7397 | 0.8015 | 2.8841 | |
| BT-549 | TNBC | Basal B | Selumetinib | MEK | MAPK | 10 | uM | 12305.155 | 0.6733 | 0.7437 | 2.8841 | |
| BT-549 | TNBC | Basal B | Selumetinib | MEK | MAPK | 50 | uM | 12305.155 | 0.6236 | 0.6979 | 2.8841 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.000128 | uM | 10755.146 | 0.9439 | 0.8613 | 0.8035 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.00064 | uM | 10755.146 | 0.9384 | 0.8478 | 0.8035 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.0032 | uM | 10755.146 | 0.9849 | 0.9625 | 0.8035 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.016 | uM | 10755.146 | 0.9853 | 0.9634 | 0.8035 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.08 | uM | 10755.146 | 0.9257 | 0.8169 | 0.8035 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.4 | uM | 10755.146 | 0.9148 | 0.7902 | 0.8035 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 2 | uM | 10755.146 | 0.9123 | 0.7841 | 0.8035 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 10 | uM | 10755.146 | 0.9282 | 0.8229 | 0.8035 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 50 | uM | 10755.146 | 0.8868 | 0.7223 | 0.8035 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.000128 | uM | 12070.155 | 1.0267 | 1.0454 | 1.1729 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.00064 | uM | 12070.155 | 0.9793 | 0.9647 | 1.1729 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.0032 | uM | 12070.155 | 1.0024 | 1.0041 | 1.1729 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.016 | uM | 12070.155 | 1.0146 | 1.0248 | 1.1729 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.08 | uM | 12070.155 | 0.9838 | 0.9723 | 1.1729 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.4 | uM | 12070.155 | 0.9556 | 0.9241 | 1.1729 | |
| CAMA-1 | HR+ | Luminal | Selumetinib | MEK | MAPK | 2 | uM | 12070.155 | 0.9322 | 0.8838 | 1.1729 |